Before the approval of trastuzumab deruxtecan (T‐DXd) in August 2022 by the US Food and Drug Administration (FDA) in previously treated mNSCLC, patients with mNSCLC with HER2 mutations had been treated generally with chemotherapies or immune checkpoint inhibitors (ICIs) in first‐line treatments similar to treatment strategies in NSCLC with non‐actionable biomarkers [18, 19, 20, 21]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.